Medicale I Department, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
"Saint Spiridon" County Hospital, 700111 Iasi, Romania.
Medicina (Kaunas). 2022 Apr 19;58(5):562. doi: 10.3390/medicina58050562.
Background and Objectives: The COVID-19 pandemic has had a considerable impact on inflammatory bowel disease (IBD) patients by limiting their access to medical services due to restrictions and the reorganization of the healthcare systems, which affects their quality of life (QoL). We aimed to assess the impact of the COVID-19 pandemic on the QoL of patients with IBD. Materials and Methods: We conducted a descriptive observational study, which included 90 adult patients diagnosed with IBD. The study sample consisted of two subgroups: a retrospective-pre-pandemic group (group A) and a prospective-pandemic group (group B). Group A included 45 IBD patients who were evaluated in 2018. Group B included 45 patients with confirmed diagnosis of IBD, evaluated between June and December 2021—the period of the COVID-19 pandemic (prospective), consecutively recruited. All the patients filled in a QoL assessment questionnaire—IBDQ-32. Subsequently, the two samples were comparatively assessed. Results: The average values of the IBDQ scores were significantly lower in 2021 compared to those recorded in 2018: 145.56 vs. 128.3 (p < 0.05). We also we found significant differences between the subscores: IBDQ1 (p = 0.043), IBDQ2 (p = 0.034), IBDQ3 (p = 0.045), IBDQ4 (p = 0.025). Conclusions: IBDQ scores were significantly lower in 2021 compared to 2018 (p < 0.05), showing that during the COVID-19 pandemic, patients with IBD had a more influenced QoL.
由于医疗服务限制和医疗系统的重新组织,COVID-19 大流行对炎症性肠病(IBD)患者产生了重大影响,这影响了他们的生活质量(QoL)。我们旨在评估 COVID-19 大流行对 IBD 患者 QoL 的影响。
我们进行了一项描述性观察研究,纳入了 90 名成年 IBD 患者。研究样本包括两个亚组:回顾性-大流行前组(A 组)和前瞻性-大流行组(B 组)。A 组包括 45 名 2018 年评估的 IBD 患者。B 组包括 45 名确诊 IBD 的患者,在 COVID-19 大流行期间(前瞻性),即 2021 年 6 月至 12 月连续招募。所有患者均填写了 QoL 评估问卷-IBDQ-32。随后,对两个样本进行了比较评估。
2021 年 IBDQ 评分的平均值明显低于 2018 年记录的值:145.56 对 128.3(p < 0.05)。我们还发现了亚评分之间的显著差异:IBDQ1(p = 0.043)、IBDQ2(p = 0.034)、IBDQ3(p = 0.045)、IBDQ4(p = 0.025)。
与 2018 年相比(p < 0.05),2021 年 IBDQ 评分明显降低,表明 COVID-19 大流行期间,IBD 患者的 QoL 受到更大影响。